KR20230098762A9 - 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 - Google Patents
아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물Info
- Publication number
- KR20230098762A9 KR20230098762A9 KR1020230081877A KR20230081877A KR20230098762A9 KR 20230098762 A9 KR20230098762 A9 KR 20230098762A9 KR 1020230081877 A KR1020230081877 A KR 1020230081877A KR 20230081877 A KR20230081877 A KR 20230081877A KR 20230098762 A9 KR20230098762 A9 KR 20230098762A9
- Authority
- KR
- South Korea
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- cell proliferative
- proliferative disorder
- Prior art date
Links
- -1 aryl amide Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Emergency Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/028575 WO2022018875A1 (ja) | 2020-07-22 | 2020-07-22 | アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物 |
| KRPCT/JP2020/028575 | 2020-07-22 | ||
| KR1020210095267A KR102550455B1 (ko) | 2020-07-22 | 2021-07-21 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210095267A Division KR102550455B1 (ko) | 2020-07-22 | 2021-07-21 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230098762A KR20230098762A (ko) | 2023-07-04 |
| KR20230098762A9 true KR20230098762A9 (ko) | 2024-03-25 |
Family
ID=79729374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210095267A KR102550455B1 (ko) | 2020-07-22 | 2021-07-21 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
| KR1020230081877A KR20230098762A9 (ko) | 2020-07-22 | 2023-06-26 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210095267A KR102550455B1 (ko) | 2020-07-22 | 2021-07-21 | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 |
Country Status (3)
| Country | Link |
|---|---|
| JP (3) | JPWO2022018875A1 (ko) |
| KR (2) | KR102550455B1 (ko) |
| WO (1) | WO2022018875A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023003014A1 (ja) * | 2021-07-21 | 2023-01-26 | 中外製薬株式会社 | アリールアミド誘導体の製造方法 |
| JPWO2023204259A1 (ko) * | 2022-04-20 | 2023-10-26 | ||
| WO2024010925A2 (en) * | 2022-07-08 | 2024-01-11 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1674452A4 (en) * | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
| AU2004293017B2 (en) * | 2003-11-19 | 2010-08-19 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
| MY144232A (en) * | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| CN103140221A (zh) * | 2010-08-10 | 2013-06-05 | 盐野义制药株式会社 | 新型杂环衍生物和含有其的药物组合物 |
| US20130123255A1 (en) * | 2011-11-10 | 2013-05-16 | Chugai Seiyaku Kabushiki Kaisha | Combination of a pi3k inhibitor and a mek inhibitor |
| JP2016034900A (ja) * | 2012-11-26 | 2016-03-17 | 中外製薬株式会社 | ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法 |
| CN104803996A (zh) * | 2014-01-27 | 2015-07-29 | 天津滨江药物研发有限公司 | 作为蛋白激酶抑制剂的氮杂环类化合物及其制备方法 |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| PE20231094A1 (es) * | 2020-07-22 | 2023-07-18 | Chugai Pharmaceutical Co Ltd | Composicion que contiene un derivado de arilamida |
-
2020
- 2020-07-22 JP JP2022538564A patent/JPWO2022018875A1/ja active Pending
- 2020-07-22 WO PCT/JP2020/028575 patent/WO2022018875A1/ja active Application Filing
-
2021
- 2021-07-21 KR KR1020210095267A patent/KR102550455B1/ko active IP Right Grant
- 2021-07-26 JP JP2021121960A patent/JP7168734B2/ja active Active
-
2022
- 2022-10-27 JP JP2022172687A patent/JP2023011759A/ja active Pending
-
2023
- 2023-06-26 KR KR1020230081877A patent/KR20230098762A9/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022018875A1 (ko) | 2022-01-27 |
| JP7168734B2 (ja) | 2022-11-09 |
| JP2022145416A (ja) | 2022-10-04 |
| KR20230098762A (ko) | 2023-07-04 |
| JP2023011759A (ja) | 2023-01-24 |
| WO2022018875A1 (ja) | 2022-01-27 |
| KR20220012195A (ko) | 2022-02-03 |
| KR102550455B1 (ko) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230098762A9 (ko) | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 | |
| EP3777888A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| MY150032A (en) | Heterocyclic amide compounds as protein kinase inhibitors | |
| GB2599045B (en) | Prevention of dripping of material for material injection | |
| EP4175629A4 (en) | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| IL289213A (en) | A pharmaceutical preparation for tumor treatment | |
| IL275573A (en) | Methods and preparations for the treatment of hypercytokinemia and severe influenza or for their prevention | |
| EP4074316A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER | |
| EP3936124A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES | |
| IL309666A (en) | Aryl compounds and pharmaceutical preparations that modulate IKZF2 | |
| SG11202106163RA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient | |
| EP3777847A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF FIBROSIS | |
| IL289657A (en) | Pharmaceutical formulations containing gaboxadol for medical treatment | |
| ZA202007616B (en) | Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative | |
| EP4174087A4 (en) | MEDICATION FOR TUMOR TREATMENT | |
| ZA202004702B (en) | Amino acid derivatives containing a disulfanyl group as an inhibitor of nep and apn for the prevention and treatment of trigeminal nerve pain | |
| SG11202108656UA (en) | Pharmaceutical composition for preventing in-stent restenosis | |
| KR102316727B9 (ko) | 아토피성 질환 예방 또는 치료용 약학적 조성물 | |
| EP3919063A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF LYSOSOMIC STORAGE DISEASES | |
| EP3960243A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF THERAPY-RESISTANT CANCER | |
| EP3527217A4 (en) | USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING OR PREVENTING CONVULSIONS | |
| ZA201902340B (en) | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer | |
| PL3650024T3 (pl) | Kompozycja farmaceutyczna do podawania donosowego, zawierająca ryfampicyny, do leczenia otępienia | |
| EP3530269A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES AND / OR HYPERLIPIDEMIA COMPRISING MIDORINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | |
| EP3466421A4 (en) | COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF A PERIPHERAL NERVOUS SYSTEM DISORDER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| A201 | Request for examination |